Digest Network Come funziona
Network
/
Società
Ot
Non verificato

Otsuka Pharmaceutical Co., Ltd.

Di cosa scriviamo

BiotecnologiaFarmaceuticaIndustriaMedicina - VarieSalute

23 comunicati stampa

Guarda tutti i comunicati
22/09/2026
Industria
Salute
Igiene alimentare
Medicina - Varie
Scienza
Farmaceutica
Biotecnologia
Otsuka Announces Transformative Phase 3 FUSION Results for Ulefnersen, Bringing the FUS-ALS Community Closer to a Potential Targeted Treatment
Fonte
Otsuka Pharmaceutical Co., Ltd.
Emittente
Business Wire
1.00
0
19/09/2026
Scienza
Biotecnologia
Farmaceutica
Salute
Psichiatria
Medicina - Varie
Industria
Otsuka Presents New Phase 3b Results for SIMTRIYO® (centanafadine) Highlighting Consistent Improvements Across ADHD Symptoms, Anxiety, and Associated Features in Adults with ADHD and Comorbid Anxiety Disorders at Psych Congress 2026
Fonte
Otsuka Pharmaceutical Co., Ltd.
Emittente
Business Wire
1.00
0
03/08/2026
Otsuka Unveils Unprecedented Phase 3 VISIONARY Two-Year eGFR Results Demonstrating VOYXACT® (sibeprenlimab-szsi) Stabilizes Kidney Function Decline to Baseline Physiologic Rate, Fundamentally Altering Disease Progression in IgA Nephropathy (IgAN)
Fonte
Otsuka Pharmaceutical Co., Ltd.
Emittente
Business Wire
1.00
0
25/07/2026
Biotecnologia
Sanità
Igiene alimentare
Salute
Farmaceutica
Otsuka Receives FDA Approval for First-in-Class SIMTRIYO® (centanafadine) for the Treatment of Attention-Deficit Hyperactivity Disorder (ADHD) in Adults and Pediatric Patients Aged 6 Years and Older
Fonte
Otsuka Pharmaceutical Co., Ltd.
Emittente
Business Wire
1.00
0
01/07/2026
Industria
Scienza
Biotecnologia
Farmaceutica
Sanità
Salute
Igiene alimentare
Medicina - Varie
Otsuka Reports Positive Phase 3 VISIONARY Two-Year eGFR Results Demonstrating VOYXACT® (sibeprenlimab-szsi) Prevented Progression to Kidney Failure and Improved Kidney Function in IgA Nephropathy (IgAN)
Fonte
Otsuka Pharmaceutical Co., Ltd.
Emittente
Business Wire
1.00
0
25/06/2026
Industria
Psichiatria
Igiene alimentare
Salute
Medicina - Varie
Farmaceutica
Biotecnologia
Otsuka Announces Positive Phase 3b Results for Centanafadine in Adults with ADHD and Comorbid Anxiety
Fonte
Otsuka Pharmaceutical Co., Ltd.
Emittente
Business Wire
1.00
0
12/06/2026
Mercato azionario
Biotecnologia
Sanità
Psichiatria
Salute
Farmaceutica
Otsuka Completes Acquisition of Transcend Therapeutics to Advance Next-Generation Neuropsychiatric Treatments
Fonte
Otsuka Pharmaceutical Co., Ltd.
Emittente
Business Wire
1.00
0
04/06/2026
Otsuka Presents Positive Interim Phase 3 VISIONARY eGFR Data Showing VOYXACT® (sibeprenlimab-szsi) Preserved Kidney Function Over 12 Months in IgA Nephropathy (IgAN)
Fonte
Otsuka Pharmaceutical Co., Ltd.
Emittente
Business Wire
1.00
0
28/05/2026
Scienza
Biotecnologia
Farmaceutica
Salute
Igiene alimentare
Medicina - Varie
Eventi
Industria
Otsuka Presents New Phase 3 Post Hoc Analyses of Centanafadine Highlighting Improvement in Executive Function and Emotional Dysregulation in Adults with ADHD at the 2026 American Society of Clinical Psychopharmacology (ASCP) Annual Meeting
Fonte
Otsuka Pharmaceutical Co., Ltd.
Emittente
Business Wire
1.00
0
25/03/2026
Eventi
Industria
Sanità
Igiene alimentare
Salute
Farmaceutica
Medicina - Varie
Otsuka Showcases New Efficacy and Safety Data of VOYXACT® (sibeprenlimab-szsi) in Patients with IgA Nephropathy (IgAN) at the 2026 ISN World Congress of Nephrology Highlighting the Impact of APRIL Inhibition
Fonte
Otsuka Pharmaceutical Co., Ltd.
Emittente
Business Wire
1.00
0

Recapiti

Social Media

Seguaci
0
Compatibilità
0